A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Фаза 3
Завершено
NCT00699751
| Заболевание | Hormone Refractory Prostate Cancer, Bone Metastases |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Bayer |
|---|
| Статус | Завершено |
|---|
| Участники | 921 участн. |
|---|
| Вмешательство | Radium-223 dichloride (Xofigo, BAY88-8223), Best standard of care (BSoC) |
|---|
| Дата начала | 12.06.2008 |
|---|
| Дата завершения | 15.07.2011 |
|---|
| Публикация результатов | 7.05.2014 |
|---|
Кратко
ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) is an international Phase III clinical study to evaluate the efficacy and safety of Radium-223 dichloride in patients with hormone refractory prostate cancer and skeletal metastases.
Overall Survival
From randomization to death due to any cause until approximately 3 years after start of enrollment, the data was collected up to the second data analysis date (15 JUL 2011) · Months
| Radium-223 Dichloride (Xofigo, BAY88-8223) | 14.9 Months |
|---|
| Placebo | 11.3 Months |
|---|
| p-value | 0.00005 |
|---|
| Hazard Ratio (HR) | 0.691 (95% CI 0.578–0.827) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.